Second generation benzofuranone ring substituted noscapine analogs: synthesis and biological evaluation.

@article{Mishra2011SecondGB,
  title={Second generation benzofuranone ring substituted noscapine analogs: synthesis and biological evaluation.},
  author={Ram Chandra Mishra and Prasanthi Karna and Sushma R Gundala and Vaishali Pannu and Richard A. Stanton and Kamlesh Kumar Gupta and Mitchell Robinson and Manu Lopus and Leslie Wilson and Maged Henary and Ritu Aneja},
  journal={Biochemical pharmacology},
  year={2011},
  volume={82 2},
  pages={
          110-21
        }
}

Figures and Tables from this paper

Design, synthesis and biological evaluation of di-substituted noscapine analogs as potent and microtubule-targeted anticancer agents.
Taking aim at a dynamic target: Noscapinoids as microtubule-targeted cancer therapeutics.
Rational Design, Synthesis, and Biological Evaluation of Third Generation α-Noscapine Analogues as Potent Tubulin Binding Anti-Cancer Agents
TLDR
The study reported here identified potent, third generation noscapinoids as new anti-cancer agents that perturbed DNA synthesis, delayed the cell cycle progression at G2/M phase, and induced apoptotic cell death in cancer cells.
A new antiproliferative noscapine analogue: chemical synthesis and biological evaluation
TLDR
This novel compound has a more potent cytotoxic effect on cancer cell lines than its parent, noscapine, and hence should be of interest as a potential anti-cancer drug.
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
TLDR
A number of noscapine analogues possessing various modifications have been described within the literature and have shown significantly improved antiprolific profiles for a large variety of cancer cell lines.
...
...

References

SHOWING 1-10 OF 51 REFERENCES
Development of a Novel Nitro-Derivative of Noscapine for the Potential Treatment of Drug-Resistant Ovarian Cancer and T-Cell Lymphoma
TLDR
9-nitro-nos has great potential to be a novel therapeutic agent for ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs.
THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS.
TLDR
A phytochemical investigation of the plant Vinca rosea Linn has demonstrated that a number of alkaloidal substances can be obtained with antitumor activity, including vinblastine, vincristine, and vinrosidine, which are capable of prolonging and/or “curing” mice of the P-1534 leukemia.
Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent
TLDR
A simple, sensitive, quantitative, selective, and less time-consuming high-performance liquid chromatography (HPLC) method for determination of noscapine and to study its pharmacokinetics in mice models is developed.
Rational design of the microtubule-targeting anti-breast cancer drug EM015.
TLDR
A new tubulin-binding semisynthetic compound, EM015, is a selective and potent anti-breast cancer agent and displays a 20-fold lower IC(50) against many tumor cells compared with the founding compound.
Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation.
TLDR
Two brominated derivatives of noscapine, 5- Br-nosc and reduced 5-bromonoscapine (Rd 5-Br- nosc) have higher tubulin binding activity than nos capine and affect tubulin polymerization differently from noscapINE, and are able to arrest cell cycle progression at mitosis at concentrations much lower than Noscapine.
Targeting microtubules for cancer chemotherapy.
TLDR
Investigation of the mechanisms of action of microtubule-targeting drugs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance may provide more effective therapeutic options for cancer patients.
Identification of novel and improved antimitotic agents derived from noscapine.
TLDR
The discovery of a novel regioselective O-demethylation facilitated the synthesis of the potent aniline 6, which arrests mammalian cells in the G2/M phase of the cell cycle at 0.1 microM and also affects tubulin polymerization.
Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses
TLDR
Oral noscapine has the potential to be an effective chemotherapeutic agent for the treatment of human cancer and showed little or no toxicity to kidney, liver, heart, bone marrow, spleen or small intestine at tumor-suppressive doses.
...
...